“Liisa’s extensive experience in R&D, business development, and global operations will significantly enhance our board’s competencies and support our long-term strategy. Mark’s experience in delivering biotech programs for infectious, immunological, and inflammatory diseases, resulting in numerous marketing approvals, makes him an ideal fit as Chair of the Innovation Committee,” says Jesper Brandgaard, Chairman of LEO Pharma’s Board of Directors.

Liisa Hurme

Liisa Hurme brings over 20 years of experience in the chemical and healthcare industries, with expertise in R&D, business development, global supply chains, and operations. She joined Orion Corporation in 1999 and became President and CEO in 2022. Liisa also chairs the Board at the Chemical Industry Federation of Finland and has served on various company and industry boards. She holds a doctorate in biochemistry from the University of Helsinki.

Mark Levick

Mark Levick is a former EU medicines regulator and CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ. His expertise was gained through a successful career as a practicing specialist physician in Australia and the UK, before leading global R&D groups at GlaxoSmithKline and Novartis in the UK, US, Switzerland and Iceland. Mark is also member of the Board at InterAx, a Swiss biotech company that uses artificial intelligence and human cell-based pharmacology to develop innovative medicines.

Both Liisa Hurme and Mark Levick will be considered independent members of LEO Pharma’s Board of Directors.